XML 395 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
Short-Term Investments
12 Months Ended
Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Short-Term Investments Short-Term Investments
Short-term investments that the Company has the positive intent and ability to hold to maturity are carried at amortized cost and classified as held-to-maturity. Short-term investments that are not classified as held-to-maturity are carried at fair value and classified as available-for-sale. As of December 31, 2024, all of the Company’s short-term investments were classified as available-for-sale. As of December 31, 2023, the Company did not have any short-term investments. Realized gains and losses on available-for-sale investments are included in net income. Unrealized gains and losses, net of tax, on available-for-sale investments are included in the consolidated balance sheet as a component of accumulated other comprehensive income (loss).

As of December 31, 2024, the Company’s available-for-sale investments consisted of the following cost, unrealized positions and estimated fair value, disaggregated by class of instrument:

 Gross Unrealized
(in thousands)CostGainsLossesEstimated Fair Value
U.S. Treasury securities$178,016 $67 $(44)$178,039 
Corporate bonds103,970 77 (78)103,969 
Commercial paper instruments17,657 — 17,663 
Asset-backed securities1,534 — 1,539 
Total short-term investments$301,177 $155 $(122)$301,210 

As of December 31, 2024, all of the Company’s available-for-sale investments were classified as short-term investments in the consolidated balance sheet and had weighted average maturities of less than one year. The Company did not identify any other-than-temporary impairment on its available-for-sale investments during 2024.
The sale and/or maturity of available-for-sale investments resulted in proceeds of $150.3 million during 2024. There were no gross realized gains or losses in 2024. There was no realized activity during 2023, as the Company did not have any short-term investments during this period.